Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Cladribine

Review the clinical trials studying cladribine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 26

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Status: Active
Location: 20 locations
Vemurafenib and Obinutuzumab versus Standard Cladribine and Rituximab of the Treatment of Untreated Hairy Cell Leukemia
Status: Active
Location: 7 locations
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Status: Active
Location: 3 locations
Venetoclax plus CLAG-M for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: 2 locations
Venetoclax with Busulfan, Thiotepa, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients with Previously Untreated Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cladribine Plus Venetoclax for the Treatment of AML That is Relapsed or Refractory to Venetoclax and a Hypomethylating Agent
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Cladribine, Cytarabine, and Decitabine With or Without Venetoclax and Gilteritinib in Treating Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cladribine and Rituximab in Treating Patients with Hairy Cell Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax with Standard Remission Induction Chemotherapy for the Treatment of Patients with Secondary Acute Myeloid Leukemia
Status: Active
Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Cladribine, Low Dose Cytarabine, Venetoclax, and Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax in Combination with Cladribine and Cytarabine Alternating with Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Olutasidenib Combined with Co-targeted Therapy for the Treatment of Myeloid Cell Cancers in Patients with IDH1 and Co-signaling Gene Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tagraxofusp and Combination Chemotherapy for the Treatment of CD123-Positive Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients with Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Immune System Cells for the Treatment of Relapse or Refractory Hematological Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Testing the Combination of Anti-cancer Drugs, Tovorafenib plus Rituximab, in Patients with Hairy Cell Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center LAO, Columbus, Ohio
TROP2-CAR-NK for the Treatment of Patients with Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
HA-1 T TCR T cell Immunotherapy for the Treatment of Patients with Relapsed or Refractory Acute Leukemia after Donor Stem Cell Transplant
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Combination Chemotherapy with Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling by Invitation
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate before Donor Stem Cell Transplant in Treating Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Patients with Blood Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas